Supplemental Table 1. Subgroup analysis of the incidence of adverse events between patients presenting with APAP overdose who received IV NAC two-bag or three-bag regimens

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **No. of Subjects (%)** | **Two-Bag Regimen** | **Three-Bag Regimen**  | **All**  | **P or CI^** |
| < 18 years, n = | 38 | 41 | 79 |   |
| NAARs | 2 (5) | 10 (24) | 12 (15) |  0.03 |
| Hepatotoxicity | 1 (2) | 1 (3) | 2 (3) | (-0.067, 0.071)^ |
| 18-28 years, n =  | 221 | 108 | 329 |  |
| NAARs | 7 (3) | 15 (14) | 22 (7) |  <0.001 |
| Hepatotoxicity | 1 (0.5) | 1 (0.9) | 2 (0.6) | (-0.025, 0.015)^ |
| 29-45 years, n = | 100 | 61 | 161 |  |
| NAARs | 5 (5) | 13 (21) | 18 (11) |  0.003 |
| Hepatotoxicity | 3 (3) | 1 (1.6) | 4 (2.5) | (-0.033, 0.060)^  |
| 46-64 years, n = | 95 | 44 | 139 |  |
| NAARs | 5 (5) | 7 (16) | 12 (9) |  0.052 |
| Hepatotoxicity | 7 (7) | 1 (2) | 8 (6) |  (-0.018, 0.120)^ |
| ≥ 65 years, n = | 39 | 20 | 59 |  |
| NAARs | 1 (3) | 1 (5) | 2 (3) | >0.999  |
| Hepatotoxicity | 8 (20) | 7 (35) | 15 (25) |  (-0.389, 0.100)^ |
| Baseline weight ≤ 70 kg, n = | 262 | 159 | 421 |  |
| NAARs | 7 (3) | 25 (16) | 32 (8) | <0.001 |
| Hepatotoxicity | 15 (6) | 10 (6) | 25 (6) |  (-0.053, 0.041)^ |
| Baseline weight > 70 kg, n = | 230 | 115 | 345 |  |
| NAARs | 13 (6) | 21 (18) | 34 (10) | <0.001 |
| Hepatotoxicity | 4 (2) | 1 (0.9) | 5 (1) | (-0.015, 0.033)^ |
| Male, n = | 139 | 62 | 201 |  |
| NAARs | 2 (1) | 10 (16) | 12 (6) | <0.001 |
| Hepatotoxicity | 9 (7) | 4 (7) | 13 (7) |  (-0.073, 0.074)^  |
| Female, n = | 354 | 211 | 565 |  |
| NAARs | 18 (5) | 35 (17) | 53 (9) | <0.001 |
| Hepatotoxicity | 11 (3) | 7 (3) | 18 (3) |  (-0.032, 0.028)^  |
| Acute ingestion, n = | 406 | 218 | 624 |  |
| NAARs | 16 (4) | 30 (14) | 46 (7) | <0.001 |
| Hepatotoxicity | 12 (3) | 5 (2) | 17 (3) | (-0.019, 0.033)^ |
| Repeat supra therapeutic ingestions, n = | 77 | 51 | 128 |  |
| NAARs | 3 (4) | 15 (29) | 18 (14) | <0.001 |
| Hepatotoxicity | 6 (8) | 5 (10) | 11 (9) | (-0.121, 0.081)^ |
| NAARs: Non-allergic anaphylactic reaction;^ indicates 95% CI |  |  |